You're in the right place! Welcome to our newly updated ESC website.
Start exploring or use our powerful new search engine to find what you need.
28 - 31 August / Munich - Germany
19 - 20 February / Munich - Germany
20-21 March / Lisbon - Portugal
12-14 April / Paris - France
23 - 25 April / Ljubljana - Slovenia
9 - 12 May / Barcelona - Spain
12 - 13 June / Sophia Antipolis - France
11 - 13 December / Vienna - Austria
21 - 22 November / Berlin - Germany
The Working Group publishes Position Papers and Consensus Documents in the ESC journal family.
The Working Group regularly updates the list of recommended reading in your field of interest.
The Working Group comments on articles in your field of interest.
The official journal of the European Society of Cardiology and the ESC Working Group on Cardiovascular Pharmacotherapy – dedicated to interpreting and integrating new scientific developments to advance pharmacological treatment for patients with cardiovascular disease.
Up-to-date information on pharmacotherapy for cardiovascular disease prevention, and treatment of cardiovascular disease.
Our scientific statements interpret scientific evidence and give you our summary position on the topic without offering specific advice
A selection of interesting papers explained and commented on by members of the Working Group
This 2025 Focused Update addresses changes in recommendations for the treatment of dyslipidaemias based on new evidence published since the 2019 version, up until 31 March 2025.
The current Guidelines for the management of cardiovascular disease and pregnancy support health care professionals to manage and care for women with cardiovascular diseases before, during and after pregnancy.
In this iteration of the European Society of Cardiology (ESC) Clinical Practice Guidelines on Atrial Fibrillation, the task force has consolidated and evolved past approaches to develop the AF-CARE framework.
These guidelines provide a comprehensive framework for healthcare professionals, covering the entire PAAD patient journey.
These ESC/EAS Guidelines on lipids provide important new advice on patient management, which should enable more clinicians to efficiently and safely reduce CV risk through lipid modification.
